株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

A型肝炎:パイプライン製品の分析

Hepatitis A - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 219723
出版日 ページ情報 英文 34 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.81円で換算しております。
Back to Top
A型肝炎:パイプライン製品の分析 Hepatitis A - Pipeline Review, H2 2016
出版日: 2016年10月30日 ページ情報: 英文 34 Pages
概要

A型肝炎とは、A型肝炎ウイルスへの感染で発症する肝臓の炎症(刺激・腫れ)のことです。主な症状として、倦怠感や吐き気・嘔吐、肝臓の炎症、食欲不振、暗色尿、筋肉痛、黄疸などが挙げられます。主な疾病素質には、免疫系の弱体化や、違法薬物の使用(注射剤・非注射剤とも)などが含まれています。主な治療法としては、鎮吐剤や鎮痛剤などがあります。

当レポートでは、世界各国でのA型肝炎治療用のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などを調査しています。

イントロダクション

  • 調査範囲

A型肝炎の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

A型肝炎:企業で開発中の治療薬

A型肝炎:大学/機関で研究中の治療薬

A型肝炎:パイプライン製品の概況

  • 後期段階の製品
  • 初期段階の製品

A型肝炎:企業で開発中の製品

A型肝炎:大学/機関で研究中の製品

A型肝炎の治療薬開発に従事している企業

  • Beijing Minhai Biotechnology Co., Ltd
  • Sinovac Biotech Ltd.
  • Zydus Cadila Healthcare Limited

A型肝炎:治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 分子タイプ別

薬剤プロファイル

A型肝炎:最近のパイプライン動向

A型肝炎:休止中のプロジェクト

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8623IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis A - Pipeline Review, H2 2016, provides an overview of the Hepatitis A (Infectious Disease) pipeline landscape.

Hepatitis A is inflammation of the liver caused by hepatitis A virus. Symptoms include fatigue, nausea and vomiting, inflammation of the liver, loss of appetite, dark urine, muscle pain and yellowing of the skin and eyes (jaundice). Risk factors include weakened immune system and use injected or non-injected illicit drugs. Treatment includes antiemetics and pain relievers.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatitis A - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hepatitis A (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatitis A (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis A and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, IND/CTA Filed, Preclinical and Unknown stages are 1, 2, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.Hepatitis A.

Hepatitis A (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis A (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Hepatitis A (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hepatitis A (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hepatitis A (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis A (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hepatitis A (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hepatitis A (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hepatitis A Overview
  • Therapeutics Development
    • Pipeline Products for Hepatitis A - Overview
    • Pipeline Products for Hepatitis A - Comparative Analysis
  • Hepatitis A - Therapeutics under Development by Companies
  • Hepatitis A - Therapeutics under Investigation by Universities/Institutes
  • Hepatitis A - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Hepatitis A - Products under Development by Companies
  • Hepatitis A - Products under Investigation by Universities/Institutes
  • Hepatitis A - Companies Involved in Therapeutics Development
    • Beijing Minhai Biotechnology Co., Ltd
    • Indian Immunologicals Limited
    • Sinovac Biotech Ltd.
    • Zydus Cadila Healthcare Limited
  • Hepatitis A - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Molecule Type
  • Drug Profiles
    • (hepatitis A + hepatitis B + hepatitis E) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (hepatitis A + hepatitis B) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hepatitis A + hepatitis B vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hepatitis A vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hepatitis A vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hepatitis A vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hepatitis A vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Hepatitis A - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Hepatitis A, H2 2016
  • Number of Products under Development for Hepatitis A - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Hepatitis A - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2016
  • Hepatitis A - Pipeline by Indian Immunologicals Limited, H2 2016
  • Hepatitis A - Pipeline by Sinovac Biotech Ltd., H2 2016
  • Hepatitis A - Pipeline by Zydus Cadila Healthcare Limited, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Hepatitis A - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Hepatitis A, H2 2016
  • Number of Products under Development for Hepatitis A - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top